Trials / Completed
CompletedNCT03749824
Investigation of Psychophysiological Response to Aversive Stimuli Over Time With Omega-3
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- Yale-NUS College · Academic / Other
- Sex
- All
- Age
- 7 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the psychophysiological responses to aversive stimuli in a population of 133 children clinically diagnosed with conduct disorder (CD) and/or attention-deficit/hyperactivity disorder (ADHD). Participants were administered with either omega-3 or placebo for a period of 6 months and were exposed to three stimuli every three months: 1) a loud sound, 2) threatening photographs from the International Affective Picture System (IAPS), and 3) the Trier Social Stress Task (TSST). Participants' psychophysiological features of heart rate and galvanic skin conductance were measured and analyzed in relation to their omega-3/placebo condition clinical diagnosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Omega-3 | Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function. |
| DIETARY_SUPPLEMENT | Placebo Capsules | Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months. |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2018-11-21
- Last updated
- 2018-11-21
Source: ClinicalTrials.gov record NCT03749824. Inclusion in this directory is not an endorsement.